Lessons from the glitazones: A story of drug development

Lancet

Volumn 357, Issue 9271, 2001, Pages 1870-1875

  Gale, Edwin A M ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

CLINICAL TRIAL; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER FAILURE; LIVER TOXICITY; MARKET; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0035832506     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04960-6     Document Type: Review

References (45)

1. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
2. PPARγ, the ultimate thrifty gene
3. PPaRγ: Adipogenic regulator and thiazolidinione receptor
4. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes
5. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus
6. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
7. Placebo-controlled trials and active-control trials in the evaluation of new treatment. I: Ethical and scientific issues
8. Placebo-controlled trials and active-control trials in the evaluation or new treatments II: Practical issues and specific cases
9. Too soon to market?
10. Hepatic dysfunction associated with troglitazone
11. Troglitazone (Romozon) withdrawn
12. The rise and fall of the killer drug Rezulin
13. Avandia (rosiglitazone)
14. PPARγ and colorectal cancer: Conflicts in a nuclear family
15. Thiazolidinediones: An update
16. Thiazolidinediones for type 2 diabetes: New agents reduce insulin resistance but need long term clinical trials
17. Being a modern pharmaceutical company involves making information available on clinical trial programmes
18. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients
19. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
20. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus
21. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
22. Troglitazone monotherapy improves glucose control in patients with type 2 diabetes mellitus: Randomized controlled study
23. Long term effects of troglitazone: Open label extension studies in type 2 diabetic patients
24. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes
25. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
26. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
27. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after one year of treatment in type 2 diabetic patients
28. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose in type 2 diabetic patients
29. Rosiglitazone
30. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus
31. Time to register randomised trials: The case is now unanswerable
32. The glitazones: Proceed with caution
33. Therapeutic combination of metformin and sulfonylurea, alone and in various combinations
34. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study
35. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: A randomized, controlled trial
36. Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
37. On the need for outcome trials in preventive pharmacology: Lessons from the recent experience with adverse drug reactions